Document Detail

B cell elimination in systemic lupus erythematosus.
MedLine Citation:
PMID:  23280492     Owner:  NLM     Status:  Publisher    
Systemic lupus erythematosus (SLE) is an autoimmune disorder with a worldwide distribution, potentially life-threatening with considerable morbidity. The elimination of pathogenic B cells has emerged as a rational therapeutic option. Many open label studies have reported encouraging results in which clinical and serological remission have invariably been described, often enabling the reduction of steroid and immunosuppressive treatment. However, the results from randomized controlled studies have been disappointing and several questions remain to be answered. In this review we will focus on results of B cell direct depletion in the treatment of patients with systemic lupus erythematosus.
João Furtado; David A Isenberg
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-27
Journal Detail:
Title:  Clinical immunology (Orlando, Fla.)     Volume:  146     ISSN:  1521-7035     ISO Abbreviation:  Clin. Immunol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2013-1-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883537     Medline TA:  Clin Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  90-103     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Department of Internal Medicine, Egas Moniz Hospital, Lisbon, Portugal. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia.
Next Document:  Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infe...